Switching GLP-1 Medications: How to Change Safely

Many patients reach a point where they ask about switching GLP-1 medications. Maybe the first pen caused side effects that never settled, weight loss has stalled, a shortage has made your brand hard to find, your insurance plan prefers a different product, or a new option has come onto the market. Moving from Wegovy to Mounjaro, from Ozempic to Zepbound, or from a daily injection such as Saxenda to a weekly pen is more common than most people realise. This guide explains the reasons for switching, how prescribers choose a starting dose, what to expect during the changeover and the mistakes to avoid.

This is general education, not a dosing chart for you to follow on your own. Switching must always be directed by a licensed prescriber, because the correct starting dose depends on your current dose, tolerance, health conditions and the exact products involved.

In This Guide

• Why People Consider Switching GLP-1 Medications
• Understanding the Medicines You Might Switch Between
• How Prescribers Decide the Starting Dose When Switching GLP-1 Medications
• Common Switching Scenarios
• What to Expect During the Changeover
• Mistakes to Avoid When Switching GLP-1 Medications
• Questions to Ask Your Prescriber
• Safety Checks Stay the Same
• When Switching GLP-1 Medications Is Not the Answer
• Keeping a Switching Diary

Why People Consider Switching GLP-1 Medications

• Side effects. Persistent nausea, vomiting, constipation or reflux may improve on a different molecule or a slower titration.
• Plateau or limited response. If weight loss has levelled off at the highest tolerated dose, a prescriber may consider an alternative. Read our guide to a weight loss plateau on GLP-1 before assuming a switch is needed.
• Supply problems. Shortages have forced many people to change brand or strength.
• Cost and insurance. Formularies change each year, and a plan may cover one product and not another. See how much weight loss injections cost.
• Different medical needs. A person who develops type 2 diabetes, heart disease or sleep apnoea may benefit from a product with specific approvals.
• Convenience. Moving from a daily injection to a weekly pen, or from an injection to tablets, can improve adherence.
• New evidence. Newer medicines offer different mechanisms and, in trials, different average results.

Understanding the Medicines You Might Switch Between

Medicine	Active ingredient	How it works	Frequency
Wegovy / Ozempic	Semaglutide	GLP-1 receptor agonist	Weekly
Mounjaro / Zepbound	Tirzepatide	Dual GIP and GLP-1 receptor agonist	Weekly
Saxenda	Liraglutide	GLP-1 receptor agonist	Daily
Mysimba	Naltrexone and bupropion	Appetite and craving pathways	Daily tablets

In pivotal trials, semaglutide 2.4 mg produced an average weight loss of around 15 percent over 68 weeks, and tirzepatide produced about 15 to 21 percent over 72 weeks, depending on dose. These are averages from different trials with different populations, so they are not a promise that you will lose more on one drug. Compare them in semaglutide vs tirzepatide and Mounjaro vs Wegovy.

How Prescribers Decide the Starting Dose When Switching GLP-1 Medications

There is no single universal conversion chart, and the manufacturers do not publish one for switching between competitors’ products. Instead, clinicians use judgement guided by a few principles.

1. Consider how long you have been off treatment. If more than a few weeks have passed since your last dose, tolerance may have faded and you may need to restart at a lower dose.
2. Consider your current tolerance. If you are on a high dose with heavy side effects, a prescriber may choose a mid-level starting dose of the new drug rather than the maximum.
3. Start low and titrate if uncertain. Many prescribers begin at the label’s starting dose of the new medicine when changing molecule, and increase every four weeks as tolerated.
4. Do not overlap two GLP-1 products. Using two at the same time raises the risk of overdose and severe gastrointestinal effects.
5. Time the first dose of the new product. Typically it replaces the next scheduled weekly dose of the old product, but this depends on the products and your prescriber’s plan.

For the standard titration ladders, see the Wegovy dosing schedule and the Mounjaro dosing schedule.

Common Switching Scenarios

Wegovy or Ozempic to Mounjaro or Zepbound

This is the most frequent switch. Because tirzepatide acts on two receptors, some people who plateau on semaglutide see further weight loss. Prescribers often restart at 2.5 mg weekly and move up in four-week steps, although some choose a higher starting step for patients who have tolerated high-dose semaglutide for a long time. Expect stomach symptoms to return at the start. Tell your prescriber if you use oral contraceptives, because tirzepatide can reduce their effect; see GLP-1 medicines, pregnancy and contraception.

Mounjaro or Zepbound to Wegovy

People change in this direction because of cost, supply, side effects or a specific indication such as cardiovascular risk reduction. Wegovy restarts at 0.25 mg and rises through five steps to 2.4 mg, so the change can feel slow. Your prescriber may allow you to move faster if you recently used a comparable medicine, but this must be a clinical decision.

Ozempic to Wegovy (same molecule)

Both contain semaglutide, so the switch is simpler, but the pens and dose ladders differ. Read the Ozempic vs Wegovy difference for details.

Daily Saxenda to a weekly pen

Moving from liraglutide to semaglutide or tirzepatide usually produces larger average weight loss and requires injecting less often. The new medicine is usually started at its own starting dose.

Injection to tablets, or tablets to injection

Some people stop injections because of needle fear, travel or cost, and try Mysimba. Others add an injection after tablets prove insufficient. Read our Mysimba guide to understand the differences.

What to Expect During the Changeover

• Side effects may return. Nausea, fullness and constipation often reappear when you start a new molecule, even if you tolerated the last one well.
• Appetite effects may change. Some people feel stronger appetite suppression with tirzepatide; others feel little difference.
• Weight may move in either direction at first. Water shifts and a lower starting dose can cause a short pause before progress resumes.
• Your schedule may shift. Agree on a new injection day if needed, keeping at least three days between doses.
• Follow-up matters. Book a review after two to four weeks.

Eat smaller meals, drink enough fluid and keep protein high, as described in what to eat on GLP-1 medication. If you miss doses during the transition, see what to do after a missed dose.

Mistakes to Avoid When Switching GLP-1 Medications

1. Using both products during the changeover.
2. Assuming milligrams are interchangeable between brands. They are not.
3. Starting a high dose of the new drug without medical advice.
4. Buying a replacement from an unverified seller because your usual pen is out of stock. Read our safe buying guide.
5. Using leftover pens past their discard date.
6. Skipping your prescriber review.
7. Switching purely because of social media claims about one drug being stronger.

Questions to Ask Your Prescriber

• Why do you recommend a switch, and what outcome should I expect?
• What starting dose will I use, and how quickly can I increase?
• When should I take my first dose of the new medicine?
• How should I manage side effects during the change?
• What will it cost, and will my insurance cover it?
• What is the plan if the new medicine does not work either?

Safety Checks Stay the Same

Whichever product you choose, the same contraindications apply: personal or family history of medullary thyroid carcinoma, MEN 2, pregnancy, breastfeeding and allergy to the ingredients. Review who should not take GLP-1 medicines before you change, and seek urgent help for severe abdominal pain, repeated vomiting or signs of an allergic reaction. For official safety updates, see the FDA drug information pages.

When Switching GLP-1 Medications Is Not the Answer

Before changing, review the basics. Are you injecting on schedule and storing pens correctly? Is your protein intake adequate? Are you sleeping enough? Are other medicines promoting weight gain? A switch cannot fix inconsistent habits. If you are at a healthy weight and simply want to maintain, ask about a maintenance plan instead; see maintaining weight after reaching your goal.

If you are considering switching GLP-1 medications, our team can explain how a physician-reviewed assessment works. Contact us with your questions, and bring your current dose history to the conversation.

Keeping a Switching Diary

Record your last dose of the old medicine, the first dose of the new one, side effects by day, weight once a week and any questions for your prescriber. A simple diary makes your review faster and helps your clinician judge whether the new medicine is working. Photograph the pen label and keep your prescription, because dose records are useful if you need replacement supplies or a second opinion.

Practical Checklist for Switching GLP-1 Medications

Before you commit to switching GLP-1 medications, run through a short checklist with your prescriber. Confirm the reason for the change, the date of your last dose, the product and strength you will start, and the date of your first review. Check that your pharmacy has stock of the new pen and that your insurance or payment plan covers it, because an unplanned gap forces a restart. People who plan well find that switching GLP-1 medications is smoother and safer than those who react to a shortage at the last minute. Keep the old pen packaging until the transition is complete, record side effects daily for the first month and never take the old and new medicine on the same day unless a prescriber has told you to.

How Long Until You Know if Switching GLP-1 Medications Has Worked?

Judge a new medicine over weeks, not days. Most prescribers want to see at least eight to twelve weeks on a stable dose before deciding whether switching GLP-1 medications has helped, because appetite effects build through the titration steps and early water shifts mask fat loss. Track weekly average weight, waist, hunger across the week and side effects. If the new medicine is tolerated and weight is trending down, stay the course. If side effects are severe or there is no benefit after a fair trial, discuss the next option rather than switching GLP-1 medications repeatedly, which can make results hard to interpret.

Editorial Standards and Sources

This guide was prepared by the Weight Lose Solution clinical content team. Medicine information is checked against official product labels and published trial data, and we update articles when guidance changes. It is educational only: prescription treatments are dispensed after an online assessment and approval by a licensed physician, and your own prescriber always takes priority.

Key sources used across our guides:

• Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
• U.S. Food and Drug Administration drug information and approved product labelling.
• World Health Organization obesity and overweight fact sheet.

Related Guides and Next Steps

Continue your research with these related guides from our clinical content team:

• Semaglutide vs tirzepatide
• Mounjaro vs Wegovy
• Ozempic vs Wegovy difference
• Wegovy dosing schedule
• How to inject a weight loss pen
• Weight loss plateau on GLP-1
• Browse prescription weight loss medications

Frequently Asked Questions About Switching GLP-1 medications

Medical disclaimer: this article is for general education and is not medical advice. Prescription treatments are dispensed only after an online health assessment and approval by a licensed physician. Always follow the guidance of your own prescriber and the patient information leaflet.